Table 1.
Characteristics of Patients and Transplant Course
| Parameter | No. (%) of Patients |
|---|---|
| Age, years | |
| <30 | 7 (7.4) |
| 30–39 | 13 (13.8) |
| 40–49 | 19 (20.2) |
| 50–59 | 28 (29.8) |
| ≥60 | 27 (28.7) |
| Sex | |
| Male | 53 (56.4) |
| Female | 41 (43.6) |
| Underlying diagnosis | |
| Leukemia | 44 (46.8) |
| Lymphoma | 26 (27.7) |
| Multiple myeloma | 8 (8.5) |
| Myelodysplastic syndrome | 12 (12.8) |
| Other | 4 (4.3) |
| Prior antibiotics (within 14 days before study period) | |
| No | 52 (55.3) |
| Yes | 42 (44.7) |
| Conditioning regimen | |
| Non-myeloablative | 16 (17) |
| Reduced intensity | 21 (22.3) |
| Myeloablative | 57 (60.6) |
| T-cell depletion | |
| No | 52 (55.3) |
| Yes | 42 (44.7) |
| Stem cell source | |
| Peripheral blood | 71 (75.5) |
| Umbilical cord | 23 (24.5) |
| Time to engraftment, daysa,b | |
| <14 | 70 (74.5) |
| ≥14 | 24 (25.5) |
| Feverb | |
| No | 16 (17) |
| Yes | 78 (83) |
| Antibiotics administeredb,c | |
| Vancomycin | 85 (90.4) |
| Fluoroquinolone | 33 (35.1) |
| Metronidazole | 30 (31.9) |
| Beta-lactamd | 82 (87.2) |
| Bloodstream infectionb,e | |
| Vancomycin-resistant Enterococcus | 9 (9.6) |
| Gram-negative bacilli, aerobic | 10 (10.6) |
| Other organism | 3 (3.2) |
| None | 72 (76.6) |
| Vital statusb | |
| Alive | 92 (97.9) |
| Dead | 2 (2.1) |
| Total | 94 (100) |
a Engraftment was defined as an absolute neutrophil count of >500 cells/µL for 3 consecutive days.
b Assessed during inpatient allogeneic hematopoietic stem cell transplantation hospitalization, from 15 days before transplant to 35 days after transplant.
c Antibiotic variables are not mutually exclusive and do not sum to 100%.
d Beta-lactams include cephalosporins, beta-lactam–beta-lactamase combinations, and carbapenems.
e Positive bacteremia values not meeting standard Centers for Disease Control and Prevention definitions of a laboratory-confirmed bloodstream infection (eg, a single positive blood culture for coagulase-negative Staphylococcus) [44] were excluded.